Maria Antonietta Ajmone-Cat Selected Research

Neoplasms (Cancer)

1/2022	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition.
1/2022	Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
3/2016	Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Antonietta Ajmone-Cat Research Topics

Disease

7	Inflammation (Inflammations) 10/2019 - 08/2002
3	Neoplasms (Cancer) 01/2022 - 03/2016
3	Diffuse Intrinsic Pontine Glioma 01/2022 - 09/2020
3	Encephalitis (Encephalitis, Rasmussen) 06/2010 - 03/2003
2	Glioma (Gliomas) 01/2022 - 03/2016
2	Glioblastoma (Glioblastoma Multiforme) 09/2020 - 03/2016
2	Neuroinflammatory Diseases 10/2015 - 01/2012
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Sarcoma (Soft Tissue Sarcoma) 01/2019
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019
1	Gliosis 03/2016
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2016
1	Necrosis 10/2015
1	Pathologic Processes 10/2015
1	Neuroblastoma 08/2014
1	Long Term Adverse Effects 01/2013
1	Polyneuropathies (Polyneuropathy) 01/2013
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2013
1	Hypertension (High Blood Pressure) 01/2012
1	Parkinson Disease (Parkinson's Disease) 03/2010
1	Brain Diseases (Brain Disorder) 01/2008
1	Pain (Aches) 01/2008
1	Fever (Fevers) 01/2008
1	Status Epilepticus (Complex Partial Status Epilepticus) 07/2006
1	Alzheimer Disease (Alzheimer's Disease) 02/2005
1	Infections 05/2004
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2003

Drug/Important Bio-Agent (IBA)

4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 06/2010 - 03/2003
3	dipinacoline glutamateIBA 01/2022 - 09/2020
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 10/2019 - 07/2006
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2016 - 10/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016 - 08/2002
2	Interleukin-10 (Interleukin 10)IBA 01/2016 - 10/2015
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 06/2010 - 08/2002
2	ProstaglandinsIBA 06/2010 - 08/2002
2	Dinoprostone (PGE2)FDA Link 07/2006 - 01/2005
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2022
1	BMS 754807IBA 01/2022
1	RibonucleoproteinsIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	gamma-glutamylaminomethylsulfonic acid (GAMS)IBA 03/2016
1	Peptides (Polypeptides)IBA 03/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2016
1	InterleukinsIBA 01/2016
1	Interleukin-6 (Interleukin 6)IBA 01/2016
1	Lithium ChlorideIBA 01/2016
1	Interleukin-4 (Interleukin 4)IBA 10/2015
1	Uncoupling Protein 2IBA 10/2015
1	Mannose ReceptorIBA 10/2015
1	Oxidants (Oxidizing Agents)IBA 08/2014
1	AntioxidantsIBA 01/2013
1	Neuroprotective AgentsIBA 01/2013
1	Acetylcarnitine (Alcar)IBA 01/2013
1	Toxic ActionsIBA 01/2013
1	Amyloid (Amyloid Fibrils)IBA 01/2012
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2012
1	EnzymesIBA 06/2010
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 06/2010
1	Protein Isoforms (Isoforms)IBA 06/2010
1	Dopamine (Intropin)FDA LinkGeneric 03/2010
1	Oxidopamine (6 Hydroxydopamine)IBA 03/2010
1	nitroflurbiprofenIBA 02/2005
1	PPAR gammaIBA 02/2005
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2005
1	Proteins (Proteins, Gene)FDA Link 05/2004
1	Acetaminophen (Paracetamol)FDA LinkGeneric 03/2003
1	Arachidonic Acid (Vitamin F)IBA 08/2002
1	CytokinesIBA 08/2002

Therapy/Procedure

3	Therapeutics 01/2022 - 01/2013